{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:30:35Z","timestamp":1781235035994,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T00:00:00Z","timestamp":1451433600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca Nordic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40261-015-0372-9","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T04:26:43Z","timestamp":1451449603000},"page":"225-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting"],"prefix":"10.1007","volume":"36","author":[{"given":"P\u00e5l","family":"Hasvold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Hammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre E.","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingar","family":"Holme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bodeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"key":"372_CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8\u201315.","journal-title":"Circulation"},{"key":"372_CR2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115483","volume":"131","author":"DR Jacobs Jr","year":"1990","unstructured":"Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32\u201347.","journal-title":"Am J Epidemiol"},{"key":"372_CR3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","unstructured":"Collaboration Emerging Risk Factors, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993\u20132000.","journal-title":"JAMA"},{"key":"372_CR4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Bor\u00e9n J, Catapano AL, et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345\u201361.","journal-title":"Eur Heart J"},{"issue":"33","key":"372_CR5","first-page":"1635","volume":"2012","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, European Association for Cardiovascular Prevention and Rehabilitation (EACPR), ESC Committee for Practice Guidelines. CPG European guidelines on cardiovascular disease prevention in clinical practice (version 2012), et al. The Fifth Joint Task Force of the European Society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;2012(33):1635\u2013701.","journal-title":"Eur Heart J"},{"issue":"25 Suppl 2","key":"372_CR6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345.","journal-title":"Circulation"},{"key":"372_CR7","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. ILLUMINATE Investigators. Effects of torcertrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322.","journal-title":"N Engl J Med"},{"key":"372_CR8","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089\u221299.","DOI":"10.1056\/NEJMoa1206797"},{"key":"372_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","volume":"92","author":"PH Jones","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152\u201360.","journal-title":"Am J Cardiol"},{"key":"372_CR10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","volume":"51","author":"PJ Barter","year":"2010","unstructured":"Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51:1546\u201353.","journal-title":"J Lipid Res"},{"key":"372_CR11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","volume":"128","author":"SM Boekholdt","year":"2013","unstructured":"Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128:1504\u201312.","journal-title":"Circulation"},{"key":"372_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.amjcard.2014.11.043","volume":"115","author":"T Ota","year":"2015","unstructured":"Ota T, Ishii H, Suzuki S, Tanaka A, Shibata Y, Tatami Y, Harata S, Shimbo Y, Takayama Y, Kawamura Y, Osugi N, Maeda K, Kondo T, Murohara T. Relation between paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy and adverse cardiovascular events in patients with acute myocardial infarction. Am J Cardiol. 2015;115:411\u20136.","journal-title":"Am J Cardiol."},{"key":"372_CR13","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.jacc.2013.07.051","volume":"62","author":"S Acharjee","year":"2013","unstructured":"Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, et al. Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE trial. J Am Coll Cardiol. 2013;62:1826\u201333.","journal-title":"J Am Coll Cardiol"},{"key":"372_CR14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/03009734.2011.653015","volume":"117","author":"M Martinell","year":"2012","unstructured":"Martinell M, Stalhammar J, Hallqvist J. Automated data extraction\u2014a feasible way to construct patient registers of primary care utilization. Ups J Med Sci. 2012;117:52\u20136.","journal-title":"Ups J Med Sci"},{"key":"372_CR15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"key":"372_CR16","doi-asserted-by":"crossref","first-page":"f3306","DOI":"10.1136\/bmj.f3306","volume":"346","author":"C Janson","year":"2013","unstructured":"Janson C, Larsson K, Lisspers KH, St\u00e4llberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting \u03b22 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.","journal-title":"BMJ"},{"key":"372_CR17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2010.1949","volume":"305","author":"M Eklind-Cervenka","year":"2011","unstructured":"Eklind-Cervenka M, Benson L, Dahlstrom U, Edner M, Rosenqvist M, Lund LH. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA. 2011;305:175\u201382.","journal-title":"JAMA"},{"key":"372_CR18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/eurheartj\/eht438","volume":"35","author":"C Varenhorst","year":"2014","unstructured":"Varenhorst C, Jensevik K, Jernberg T, Sundstr\u00f6m A, Hasvold P, Held C, et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J. 2014;35:969\u201378.","journal-title":"Eur Heart J"},{"key":"372_CR19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","volume":"6","author":"MA Brookhart","year":"2013","unstructured":"Brookhart MA, Wyss R, Layton JB, St\u00fcrmer T. Propensity score methods for confounding control in non experimental research. Circ Cardiovasc Qual Outcomes. 2013;6:604\u201311.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"372_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i07","volume":"42","author":"JS Sekhon","year":"2011","unstructured":"Sekhon JS. Multivariate and propensity score matching software with automated balance optimization. J Stat Softw. 2011;42:1\u201352.","journal-title":"J Stat Softw"},{"key":"372_CR21","first-page":"66","volume":"3","author":"M Hemelrijck Van","year":"2012","unstructured":"Van Hemelrijck M, Harari D, Garmo H, Hammar N, Walldius G, Lambe M, et al. Biomarker-based score to predict mortality in persons aged 50\u00a0years and older: a new approach in the Swedish AMORIS study. Int J Mol Epidemiol Genet. 2012;3:66\u201376.","journal-title":"Int J Mol Epidemiol Genet"},{"key":"372_CR22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1373\/clinchem.2010.157164","volume":"3","author":"A Langsted","year":"2011","unstructured":"Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58,434 individuals from the Copenhagen General Population Study. Clin Chem. 2011;3:482\u20139.","journal-title":"Clin Chem"},{"key":"372_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjcard.2013.09.007","volume":"113","author":"K Hambraeus","year":"2014","unstructured":"Hambraeus K, Lindhagen L, Tyd\u00e9n P, Lindahl B, Lagerqvist B. Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in Sweden. Am J Cardiol. 2014;113:17\u201322.","journal-title":"Am J Cardiol"},{"key":"372_CR24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bph.12174","volume":"169","author":"A Tran-Dinh","year":"2013","unstructured":"Tran-Dinh A, Diallo D, Delbosc S, Varela-Perez LM, Dang QB, Lapergue B, et al. HDL and endothelial protection. Br J Pharmacol. 2013;169:493\u2013511.","journal-title":"Br J Pharmacol"},{"key":"372_CR25","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/eurheartj\/ehi412","volume":"26","author":"L Wilhelmsen","year":"2005","unstructured":"Wilhelmsen L, K\u00f6ster M, Harmsen P, Lappas G. Differences between coronary disease and stroke in incidence, case fatality, and risk factors, but few differences in risk factors for fatal and non-fatal events. Eur Heart J. 2005;26:1916\u201322.","journal-title":"Eur Heart J"},{"key":"372_CR26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1161\/CIRCULATIONAHA.110.964999","volume":"123","author":"K Dudas","year":"2011","unstructured":"Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation. 2011;123:46\u201352.","journal-title":"Circulation"},{"key":"372_CR27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/bmj.298.6676.784","volume":"298","author":"WY Craig","year":"1989","unstructured":"Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989;298:784\u20138.","journal-title":"BMJ"},{"key":"372_CR28","unstructured":"OECD. OECD Factbook 2011\u22122012: Economic, Environmental and Social Statistics. Adult population smoking daily. Available at: http:\/\/www.oecd-ilibrary.org\/sites\/factbook-2011-en\/12\/02\/01\/12-02-01g1.html?contentType=\/ns\/StatisticalPublication,\/ns\/Chapter&itemId=\/content\/chapter\/factbook-2011-107en&containerItemId=\/content\/serial\/18147364&accessItemIds=&mimeType=text\/html&_csp_=db2b28696cd26bcfce3036cbd611c6ac . Accessed 14 Oct 2014."},{"key":"372_CR29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/02813430500439395","volume":"24","author":"LG Persson","year":"2006","unstructured":"Persson LG, Hjalmarson A. Smoking cessation in patients with diabetes mellitus: results from a controlled study of an intervention programme in primary healthcare in Sweden. Scand J Prim Health Care. 2006;24:75\u201380.","journal-title":"Scand J Prim Health Care"},{"key":"372_CR30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.atherosclerosis.2011.10.009","volume":"220","author":"PT Skretteberg","year":"2012","unstructured":"Skretteberg PT, Grundvold I, Kjeldsen SE, Erikssen JE, Sandvik L, Liest\u00f8l K, et al. HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men. Atherosclerosis. 2012;220:250\u20136.","journal-title":"Atherosclerosis"},{"key":"372_CR31","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1185\/03007990903269112","volume":"25","author":"EM Heintjes","year":"2009","unstructured":"Heintjes EM, Penning-van Beest FJ, Johansson S, Stalenhoef AF, Herings RM. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Curr Med Res Opin. 2009;25:2621\u20139.","journal-title":"Curr Med Res Opin"},{"key":"372_CR32","unstructured":"http:\/\/www.equalis.se\/media\/41723\/u040_kvalitetsm\u00e5l_equalis_1.2.pdf . Accessed 21 May 2015."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0372-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0372-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0372-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:07:29Z","timestamp":1553612849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0372-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,30]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0372-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,30]]}}}